Top-News
Gesundheitswesen: Ausstattung u. Produkte Dänemark

Bavarian Nordic News

Aktie
WKN:  917165 ISIN:  DK0015998017 US-Symbol:  BVNKF
21,50 €
-0,29 €
-1,33%
12:20:29 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
77,77 Mio.
Marktkapitalisierung *
1,69 Mrd. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 23.06.2023

Bavarian Nordic News

07:37 Uhr - GlobeNewswire
Bavarian Nordic Announces Interim Results for the First Three Months of 2024
COPENHAGEN, Denmark , May 8, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2024. ...
29.04.24 - GlobeNewswire
Bavarian Nordic Receives 65 mEUR Contract to Supply Smallpox Vaccines for EU Strategic Reserve
COPENHAGEN, Denmark, April 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced the award of a contract valued at EUR 65 million to supply its MVA-BN ® smallpox ...
29.04.24 - GlobeNewswire
Bavarian Nordic Initiates Rolling Submission of Biologics License Application with FDA for its Chikungunya Vaccine Candidate
COPENHAGEN, Denmark, April 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced that it has initiated the rolling submission process with the U.S. Food and Drug ...
02.04.24 - GlobeNewswire
Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.
COPENHAGEN, Denmark, April 2, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that JYNNEOS ® , the only FDA-​approved mpox vaccine, is now commercially available ...
13.03.24 - GlobeNewswire
Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in Switzerland
COPENHAGEN, Denmark, March 13, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Swiss Agency for Therapeutic Products, Swissmedic, has approved ...
12.03.24 - GlobeNewswire
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
COPENHAGEN, Denmark, March 12, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company’s shares/related ...
06.03.24 - GlobeNewswire
Bavarian Nordic Publishes Annual Report 2023
COPENHAGEN, Denmark, March 6, 2024 – Bavarian Nordic A/S (OMX: BAVA) today published its Annual Report for 2023. The consolidated, audited results were in line with the ...
23.02.24 - GlobeNewswire
Bavarian Nordic’s Chikungunya Vaccine Candidate Granted Accelerated Assessment by European Medicines Agency
Accelerated assessment allows for a shorter review period with EMA. Bavarian Nordic is on track to submit its Marketing Authorisation Application for CHIKV VLP to EMA during H1 ...
21.02.24 - GlobeNewswire
Bavarian Nordic delivered record financial results in 2023
Preliminary 2023 results exceed the latest guidance and represent the best-ever financial result in the Company’s history driven by extraordinary growth in travel health and a surge in ...
22.11.23 - GlobeNewswire
Bavarian Nordic to hold Capital Markets Days in February 2024
COPENHAGEN, Denmark, November 22, 2023 – Bavarian Nordic A/S (OMX: BAVA) will hold a series of capital markets days in February 2024 for investors and analysts across ...
16.11.23 - GlobeNewswire
Bavarian Nordic Announces Interim Results for the First Nine Months of 2023
COPENHAGEN, Denmark, November 16, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results for the first nine months of 2023 and business ...
25.10.23 - GlobeNewswire
Bavarian Nordic’s Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk
COPENHAGEN, Denmark, October 25, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory ...
13.09.23 - GlobeNewswire
Bavarian Nordic Awarded Another Contract to Supply Smallpox Vaccines for EU Strategic Reserve
COPENHAGEN, Denmark, September 13, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today, that it has been awarded another contract valued at more than EUR 11 million ...
01.09.23 - 4investors
Bavarian Nordic: Enttäuschung beim COVID-19 Impfstoff
23.08.23 - 4investors
Bavarian Nordic Aktie nach Zahlen deutlich im Plus - Vorsicht bleibt aber angebracht
23.08.23 - Der Aktionär
Bavarian Nordic: Umsatzexplosion von 278 Prozent – Aktie startet durch – ein weiterer Gewinner
23.08.23 - GlobeNewswire
Bavarian Nordic Announces First Half 2023 Results
COPENHAGEN, Denmark, August 23, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first half of 2023 and ...
24.07.23 - Der Aktionär TV
Microsoft, Alphabet, AMC Entertainment, Snap, Shopify, BioNTech, Bavarian Nordic - Opening Bell
Auf die Wall Street wartet eine spannende Woche. Der Terminkalender ist pickepackevoll. Zum einen steht die Sitzung der US-​Notenbank am Mittwoch an. Zum anderen gibt es jede ...
24.07.23 - GodmodeTrader
BAVARIAN NORDIC - Hoch geflogen, tief gestürzt
24.07.23 - Der Aktionär
Bavarian Nordic: Horror‑News am Wochenende – Aktie bricht ein

Newssuche

Videos

newspaper
07.05.24 +8,72%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: NG8K9X Hebel: 26 Laufzeit: OpenEnd Einstieg: Market ... Mehr »